RET, ROS1 and ALK fusions in lung cancer

By K. Takeuchi, M. Soda, Yuki Togashi, R. Suzuki, S. Sakata, S. Hatano, R. Asaka, W. Hamanaka, H. Ninomiya, H. Uehara and 6 more. Nature Medicine, 2012

1,337 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/94cfc39af3987aff2c47620b3f55d814d1fefbd7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Mechanisms of receptor tyrosine kinase activation in cancer (2018, positive): “Likewise, oncogenic tyrosine kinase fusions involving ROS1 have been identified in ~ 1% of NSCLCs [112], as well as in IMTs, cholangiocarcinoma, and GBM [94, 113].”
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. (2016, neutral): “5 (59-84) 61 (30-93) 65 (42-93) Sex Male 9 (32) 30 (30) 62 (37) Female 19 (68) 69 (70) 107 (63) Smoking history, pack-years* Never-smoker 10 (36) 57 (58) 6 (4) # 10 3 (11) 10 (10) 11 (7) .”
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing (2012, background): “Given their reported 2%–7% frequency in lung adenocarcinoma (Bergethon et al., 2012; Takeuchi et al., 2012), our study of 24 tumor/normal pairs may not be large enough to detect these rearrangements.”
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “It is found in around 1-2% of lung adenocarcinomas and predominantly in non-smokers (143,147).”
Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma (2020, background): “, 2014), andRET fusions (Gautschi et al., 2017; Kohno et al., 2012; Takeuchi et al., 2012), a substantial proportion of LUADs still lack known or currently targetable mutations.”
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018, background): “RET rearrangement is mutually exclusive with aberrations in EGFR, KRAS, ALK, HER2, and BRAF in lung cancer.(62,64,65) RET fusion occurs more frequently in never smokers than ever smokers.”